SRR6013527
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.410
- ALLOGRAFT_REJECTION+0.380
- G2M_CHECKPOINT+0.340
- INTERFERON_GAMMA_RESPONSE+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- INTERFERON_ALPHA_RESPONSE+0.320
- INFLAMMATORY_RESPONSE+0.280
- IL6_JAK_STAT3_SIGNALING+0.260
- IL2_STAT5_SIGNALING+0.220
- COMPLEMENT+0.200
Top 10 suppressed
- APICAL_JUNCTION-0.270
- MYC_TARGETS_V1-0.270
- PANCREAS_BETA_CELLS-0.260
- PROTEIN_SECRETION-0.250
- ESTROGEN_RESPONSE_EARLY-0.210
- MYC_TARGETS_V2-0.210
- GLYCOLYSIS-0.180
- ESTROGEN_RESPONSE_LATE-0.160
- HYPOXIA-0.160
- P53_PATHWAY-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1298 | — | — | 0.752 |
| 2 | BSR_10_0136_B1_S95 | — | D | 0.735 |
| 3 | 7d3b4d06-1249-4a85-a66a-387d4e2e2cb2 | — | — | 0.732 |
| 4 | 57c4a274-647d-4499-a8f8-a79e446ab4a7 | — | — | 0.718 |
| 5 | 4ff81b7f-2dbc-453f-a68b-fe40315b2ef7 | — | — | 0.697 |
| 6 | C3N-02922 | — | cohortMD2 | 0.685 |
| 7 | R237 | — | — | 0.680 |
| 8 | TCGA-EW-A3U0-01A-11R-A22K-07 | — | D | 0.675 |
| 9 | TCGA-A2-A0SX-01A-12R-A084-07 | — | D | 0.674 |
| 10 | TCGA-BH-A0BW-01A-11R-A115-07 | — | D | 0.674 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |